Key result
Longer duration of corticosteroid therapy was associated with reduced flow-mediated dilation in patients with systemic lupus erythematosus.
Why the study?
What is the relationship between endothelial function, disease activity, cardiovascular risk factors, and corticosteroid therapy in patients with systemic lupus erythematosus?
Cross-Sectional (n=20)
What is the relationship between endothelial function, disease activity, cardiovascular risk factors, and corticosteroid therapy in patients with systemic lupus erythematosus?
In patients with systemic lupus erythematosus, endothelial dysfunction appears to be associated with long-term exposure to corticosteroids.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for corticosteroid-related endothelial dysfunction in SLE; prospective studies needed before clinical implications.
OBJECTIVES: Endothelial dysfunction is frequently present in patients with systemic lupus erythematosus and may increase their risk of premature coronary artery disease. In this pilot study we have characterized the relationship between endothelial function, measures of disease activity, and cardiovascular risk factors in patients with lupus. METHODS: Clinical characteristics and cardiovascular risk factors were evaluated in 20 patients with lupus. Flow-mediated dilation of the brachial artery was measured using high resolution ultrasound and the presence or absence of coronary calcification determined by electron-beam computed tomography. The relationship between these variables and flow-mediated dilation was determined using Spearman correlation coefficients (RHO) and Mann Whitney-Wilcoxon tests. RESULTS: Twenty patients (17 female) median age (interquartile range) 42.5 (32.0-47.5) years were studied. The median flow-mediated vasodilation was 3.6% (1.7%-7.7%). In patients with coronary calcification (n = 6), flow-mediated dilation was 2.1% (-0.42%-3.6%) compared with 4.0% (3.5%-8.3%) in those without (p = 0.12). There was no significant relationship between flow-mediated dilation and markers of disease activity, duration of disease, and cardiovascular risk factors. Lower flow-mediated dilation was associated with duration of corticosteroid therapy (RHO = -0.44, p = 0.05). CONCLUSIONS: In these preliminary results, endothelial dysfunction is associated with long-term exposure to corticosteroids.
No takes yet. Share an insight, caveat, or question.
Turner et al. (2005) conducted a cross-sectional in Systemic lupus erythematosus (n=20). Corticosteroid therapy vs. Unexposed or shorter duration was evaluated on Flow-mediated dilation of the brachial artery (RHO = -0.44, p=0.05). Longer duration of corticosteroid therapy was associated with reduced flow-mediated dilation in patients with systemic lupus erythematosus.
Synapse has enriched 10 related papers. Consider them for comparative context: